NO333189B1 - Anvendelse av buprenorfin for fremstilling av en transdermal doseringsform for behandling av medikamentavhengighet, samt sett omfattende slike doseringsformer. - Google Patents

Anvendelse av buprenorfin for fremstilling av en transdermal doseringsform for behandling av medikamentavhengighet, samt sett omfattende slike doseringsformer.

Info

Publication number
NO333189B1
NO333189B1 NO20060913A NO20060913A NO333189B1 NO 333189 B1 NO333189 B1 NO 333189B1 NO 20060913 A NO20060913 A NO 20060913A NO 20060913 A NO20060913 A NO 20060913A NO 333189 B1 NO333189 B1 NO 333189B1
Authority
NO
Norway
Prior art keywords
buprenorphine
dosage form
dosage
preparation
treatment
Prior art date
Application number
NO20060913A
Other languages
English (en)
Norwegian (no)
Other versions
NO20060913L (no
Inventor
Bruce E Reidenberg
Daniel A Spyker
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NO20060913L publication Critical patent/NO20060913L/no
Publication of NO333189B1 publication Critical patent/NO333189B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B09DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09BDISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B2101/00Type of solid waste
    • B09B2101/65Medical waste
    • B09B2101/68Transdermal patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Materials Engineering (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Drying Of Semiconductors (AREA)
  • Cephalosporin Compounds (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
NO20060913A 2003-07-25 2006-02-24 Anvendelse av buprenorfin for fremstilling av en transdermal doseringsform for behandling av medikamentavhengighet, samt sett omfattende slike doseringsformer. NO333189B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49040703P 2003-07-25 2003-07-25
PCT/US2004/024010 WO2005011579A2 (en) 2003-07-25 2004-07-26 Treatment of dependence withdrawal

Publications (2)

Publication Number Publication Date
NO20060913L NO20060913L (no) 2006-04-21
NO333189B1 true NO333189B1 (no) 2013-03-25

Family

ID=34115390

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060913A NO333189B1 (no) 2003-07-25 2006-02-24 Anvendelse av buprenorfin for fremstilling av en transdermal doseringsform for behandling av medikamentavhengighet, samt sett omfattende slike doseringsformer.

Country Status (28)

Country Link
US (1) US8637073B2 (enExample)
EP (1) EP1646328B1 (enExample)
JP (2) JP2007500134A (enExample)
KR (1) KR100829492B1 (enExample)
CN (1) CN1829482B (enExample)
AT (1) ATE375149T1 (enExample)
AU (1) AU2004261182B2 (enExample)
BR (1) BRPI0412931A (enExample)
CA (1) CA2530005C (enExample)
CY (1) CY1107262T1 (enExample)
DE (1) DE602004009449T2 (enExample)
DK (1) DK1646328T3 (enExample)
EA (1) EA009921B1 (enExample)
ES (1) ES2295929T3 (enExample)
GE (1) GEP20125454B (enExample)
HR (1) HRP20070476T3 (enExample)
IL (1) IL173346A (enExample)
IS (1) IS2630B (enExample)
MA (1) MA28004A1 (enExample)
MX (1) MXPA06000991A (enExample)
NO (1) NO333189B1 (enExample)
NZ (1) NZ545505A (enExample)
PL (1) PL1646328T3 (enExample)
PT (1) PT1646328E (enExample)
SI (1) SI1646328T1 (enExample)
UA (1) UA81056C2 (enExample)
WO (1) WO2005011579A2 (enExample)
ZA (1) ZA200510069B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1913938A1 (en) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
WO2004054553A1 (en) 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
CA2530005C (en) 2003-07-25 2011-09-27 Bruce E. Reidenberg Use of buprenorphine for the treatment of drug dependence withdrawal in a pregnant woman
CN101321554A (zh) * 2005-09-30 2008-12-10 Tti优而美株式会社 使用类阿片激动剂和/或类阿片拮抗剂的经皮药物输送系统、装置和方法
WO2009106831A2 (en) * 2008-02-28 2009-09-03 Syntropharma Limited Pharmaceutical composition
US8163731B2 (en) * 2008-08-20 2012-04-24 Rhodes Technologies Method and dosage regimens for eliminating a chemical substance in blood
WO2011116243A1 (en) 2010-03-17 2011-09-22 Method Products, Inc. Liquid cleaning compositions with lower freezing point
US11236351B2 (en) 2010-05-17 2022-02-01 Dow Agrosciences Llc Production of DHA and other LC PUFAs in plants
TW201307553A (zh) 2011-07-26 2013-02-16 Dow Agrosciences Llc 在植物中生產二十二碳六烯酸(dha)及其他長鏈多元不飽和脂肪酸(lc-pufa)之技術
TWI522101B (zh) * 2012-04-17 2016-02-21 普渡製藥有限合夥事業 處理由類鴉片引起之不利的藥效動力反應之系統和方法
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2017120417A1 (en) 2016-01-08 2017-07-13 Ohio State Innovation Foundation Treatments and prevention of opioid neonatal abstinence syndrome
CA3068036A1 (en) 2017-06-30 2019-01-03 Purdue Pharma L.P. Use to buprenorphine in combination with an opioid to treat pain
CN107648234A (zh) * 2017-08-04 2018-02-02 中国人民解放军第二军医大学 一种治疗吗啡成瘾戒断症状的阿片类药物组合物
CA3066284A1 (en) * 2018-04-09 2019-10-17 Katana Pharmaceuticals, Inc. Oxytocin compositions and methods of use
WO2021043771A1 (en) * 2019-09-02 2021-03-11 Camurus Ab Formulations and treatment methods
JP2024506861A (ja) 2021-02-01 2024-02-15 クリア サイエンティフィック,インク. 物質使用障害の治療のための隔離化合物及びその使用
WO2024036337A2 (en) * 2022-08-12 2024-02-15 Bio Ventures, Llc Deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058599A (en) * 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
DE3939376C1 (enExample) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5075341A (en) * 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
EP0432945A1 (en) * 1989-12-12 1991-06-19 Warner-Lambert Company A transdermal delivery system for treatment of cocaine and heroin addiction
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
JPH06183956A (ja) * 1992-12-24 1994-07-05 Teisan Seiyaku Kk 安定な貼付用の製剤
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
EP0821957A3 (en) 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
WO2003037313A2 (en) * 2001-10-31 2003-05-08 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
DK1485051T3 (da) 2002-03-20 2008-09-08 Euro Celtique Sa Fremgangsmåde til indgivelse af buprenorphin til behandling af depression
WO2004054553A1 (en) * 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
WO2004103317A2 (en) 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
CA2530005C (en) 2003-07-25 2011-09-27 Bruce E. Reidenberg Use of buprenorphine for the treatment of drug dependence withdrawal in a pregnant woman

Also Published As

Publication number Publication date
HRP20070476T3 (en) 2008-01-31
US8637073B2 (en) 2014-01-28
US20060240085A1 (en) 2006-10-26
WO2005011579A3 (en) 2005-06-09
JP2011252020A (ja) 2011-12-15
KR20060037400A (ko) 2006-05-03
JP2007500134A (ja) 2007-01-11
ES2295929T3 (es) 2008-04-16
MA28004A1 (fr) 2006-07-03
DE602004009449D1 (de) 2007-11-22
CA2530005A1 (en) 2005-02-10
EP1646328A2 (en) 2006-04-19
IL173346A (en) 2011-02-28
AU2004261182B2 (en) 2008-05-15
IS2630B (is) 2010-06-15
GEP20125454B (en) 2012-03-26
DK1646328T3 (da) 2008-02-04
ZA200510069B (en) 2006-10-25
WO2005011579A2 (en) 2005-02-10
MXPA06000991A (es) 2006-04-11
CY1107262T1 (el) 2012-11-21
DE602004009449T2 (de) 2008-07-24
CA2530005C (en) 2011-09-27
SI1646328T1 (sl) 2008-02-29
NO20060913L (no) 2006-04-21
IL173346A0 (en) 2006-06-11
EP1646328B1 (en) 2007-10-10
NZ545505A (en) 2010-02-26
BRPI0412931A (pt) 2006-09-26
EA009921B1 (ru) 2008-04-28
CN1829482B (zh) 2012-10-10
CN1829482A (zh) 2006-09-06
AU2004261182A1 (en) 2005-02-10
EP1646328A4 (en) 2006-08-30
PL1646328T3 (pl) 2008-03-31
KR100829492B1 (ko) 2008-05-19
EA200600200A1 (ru) 2006-06-30
UA81056C2 (en) 2007-11-26
IS8187A (is) 2005-12-19
PT1646328E (pt) 2007-10-24
ATE375149T1 (de) 2007-10-15

Similar Documents

Publication Publication Date Title
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
NO20014842D0 (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
WO1999011250A3 (en) Noribogaine in the treatment of pain and drug addiction
AU4743601A (en) Neutral antagonists and use thereof in treating drug abuse
JP2002523370A5 (enExample)
DE60320770D1 (de) Verfahren zur verabreichung von buprenorphin zur behandlung von depression
DK1572167T3 (da) Transdermal buprenophindoseringsbehandlingsplan for analgesi
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
ATE405272T1 (de) Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin
JP2007500134A5 (enExample)
UA81689C2 (ru) Способ предоперационного лечения послеоперационной боли бупренорфином
HUP9801628A2 (hu) Artritisz elleni gyógyászati készítmények
WO2008021536A3 (en) Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects
ZA202202673B (en) Methods and compositions for treating endometriosis
Tekol et al. Ephedrine diminishes some side effects of morphine
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: EURO-CELTIQUE SA, LU

MM1K Lapsed by not paying the annual fees